Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo D5W Clear all

Conditions: Acute Pain
Interventions: TRV130, Morphine, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 1 more

Conditions: Healthy
Interventions: Oritavancin, Placebo (D5W); Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Severe Sepsis, Acute Lung Injury
Interventions: High Dose Citrulline, Placebo, Low Dose Citrulline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 13 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
Interventions: Lidocaine Hydrochloride, Placebo, FOLFOX regimen; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions: Trilaciclib, Placebo, Gemcitabine, Carboplatin; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more

Conditions: Photosensitive Epilepsy
Interventions: Valproic Acid, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Chesterfield, Missouri • Nashville, Tennessee

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: 5% dextrose in water, TZP-101; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: San Francisco, California • Anderson, Indiana • Kansas City, Kansas + 3 more

Conditions: Portal Hypertension, Liver Cirrhosis
Interventions: Ifetroban, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio + 3 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Hypotension, Blood Pressure
Interventions: Dopamine, Hydrocortisone, Infusion Placebo, Syringe Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 24 Hours
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions: Milrinone, Placebo (5% Dextrose); Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 0 Hours to 168 Hours
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: NIS793, Nab-paclitaxel, Gemcitabine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Los Angeles, California • Orlando, Florida + 6 more

Conditions: Shock, Thermal Burn
Interventions: Ascorbic Acid, placebo; Drug
Lead sponsor: Clinical Evaluation Research Unit at Kingston General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Phoenix, Arizona • Bridgeport, Connecticut • Washington D.C., District of Columbia + 7 more

Conditions: Acute Ischemic Stroke
Interventions: Acetylcysteine, Dextrose in Water; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Torrance, California

Conditions: Pain, Arthrofibrosis, Osteoarthritis, Knee
Interventions: Hydrocortisone, Dextrose 5% in water (D5W); Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 83 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Defects, Congenital
Interventions: nesiritide, milrinone, placebo; Drug
Lead sponsor: John M Costello; Other
Eligibility: Not listed
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postoperative Pain in Infants
Interventions: Ketorolac Tromethamine 1 mg/kg, Ketorolac Tromethamine 0.5 mg/kg, Placebo; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 2 Months to 18 Months
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Neuropathic Pain
Interventions: Ondansetron 16 mg with Tariquidar, Ondansetron 16 mg with Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Volunteers
Interventions: ANX-042, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 19 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hepatorenal Syndrome
Interventions: Ifetroban Injection, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more

Conditions: Atrial Fibrillation Ablation
Interventions: Vitamin C, Placebo; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Alzheimer's Disease
Interventions: G-CSF; filgrastim, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 55 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Gastroesophageal Reflux, Apnea, Bradycardia
Interventions: Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W); Drug · Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Days and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hepatocellular Carcinoma
Interventions: ThermoDox, Dummy infusion; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Study of TRV130 for the Treatment of Pain After Bunionectomy

Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

Citrulline in Severe Sepsis

Lidocaine for Oxaliplatin-induced Neuropathy

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Effect of Valproic Acid Concentration on Photic Response

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

Early Blood Pressure Management in Extremely Premature Infants

Milrinone in Congenital Diaphragmatic Hernia

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

VItamin C in Thermal injuRY: The VICToRY Trial

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)

Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery

Ketorolac in Postoperative Infants: Pharmacokinetics and Safety

Tariquidar-ondansetron Combination in Neuropathic Pain

ANX-042 Healthy Volunteer Dose Escalation Study

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Vitamin C in Atrial Fibrillation Ablation

Efficacy and Safety of Filgrastim in Alzheimer's Disease

Study of Erythromycin in GER-Associated Apnea of the Newborn

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)